Floppy Iris SyndromeNCT01252472
Flomax Study for Floppy Iris Syndrome
An observational study of Floppy Iris Syndrome, run by University of Michigan at 1 site in United States.
Trial summary
Some men who have a history of use of Tamsulosin (Flomax) are at risk for a condition called Intraoperative Floppy Iris Syndrome that can develop during otherwise routine cataract surgery. It is not fully understood why this condition develops or who is at risk for developing it. Read more about this study
- Who is it for?
- Ages 18 years and older, men onlyHealthy volunteers can take part
- Conditions the study is for
- Floppy Iris Syndrome
- How many people
- 36 participants
- Where
- 1 siteUnited States
- Study dates
- Jun 2010to Dec 2013
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Men only
- Healthy volunteers accepted
- Adult, Older adult
Study population: Adult male patients seen and scheduled for cataract surgery at the Kellogg eye Centers in Ann Arbor, Livonia and Brighton campuses.
Who may be able to join
- Male
- 18 years or older
- Scheduled for Cataract Surgery
- Current or Past use of Tamsulosin (flomax)
- Blue colored iris
- For controls, no history of Flomax
Who cannot join
- Females
- Diabetes
- Glaucoma
- Use of medicated eye drops
- Trauma or prior surgery to the eye
- Black or brown iris
Trial locations and contacts
1 site in 1 country.
United States1 site
Kellogg Eye Center, 1000 Wall Street
Ann Arbor, Michigan, 48105
About this study
Official title: Diagnostic Imaging for Intraoperative Floppy Iris Syndrome
Some men who have a history of use of Tamsulosin (Flomax) are at risk for a condition called Intraoperative Floppy Iris Syndrome that can develop during otherwise routine cataract surgery. It is not fully understood why this condition develops or who is at risk for developing it. In this study the investigators will take pictures of the iris and iris blood vessels before cataract surgery. The investigators hope that the results of this study will provide a better understanding of how Intraoperative Floppy Iris Syndrome develops and give us a non-surgical way of figuring out who might develop this problem during surgery.
Read the detailed description
Male patients scheduled for cataract surgery who are currently taking tamsulosin will be recruited into the study. Age-matched male control patients undergoing cataract surgery, without a history of using any a-adrenergic antagonist medication, will also be recruited. Careful diagnostic iris evaluation using iris Fluorescein Angiography (FA) and Anterior Segment Optical Coherence Tomography (AS-OCT) will be performed prior to cataract surgery. Intraoperative findings and surgical complications will be recorded in an effort to correlate preoperative diagnostic iris FA and AS-OCT findings with presence and severity of intraoperative floppy iris syndrome (IFIS). The investigators hypothesize that males on tamsulosin will have abnormal iris blood vessels on iris FA and altered iris morphology, consistent with iris atrophy, on AS-OCT that will correlate with presence of IFIS and help elucidate the pathophysiology of tamsulosin-induced IFIS.
Male patients scheduled for cataract surgery who are currently taking tamsulosin will be eligible for enrollment into the study if they have no other conditions that affect the iris vasculature and architecture (i.e. diabetes mellitus, glaucoma, pseudoexfoliation syndrome, history of prior eye surgery or eye trauma, use of eye drops other than artificial tears and normal preoperative drops). Control patients will be eligible if they have no history of use of any a-adrenergic antagonist (tamsulosin, alfuzosin, doxazosin, or terazosin). Patients who are interested in participating will be given a copy of the study consent form to take home with them. These patients will then be contacted by the study coordinator for further discussion of the study details. Study volunteers will be asked to come to the Kellogg Eye Center any time prior to their scheduled surgery. Volunteers will undergo the informed consent process, sign the consent form and be given a study identification number, linked to the patient in a de-identified fashion, that will be used exclusively for the study. The link of the study identification number and patient will be kept in a locked cabinet in the clinic coordinator's locked office. All patient study information will be collected and encoded according to HIPAA guidelines and institutional review board approval. The investigators plan to enroll 20 patients and 10 age-matched controls in a 12-month enrollment period.
- Iris Fluorescein Angiography (FA) will be performed in the surgical eye. The volunteer will be seated at the Heidelberg Spectralis (Heidelberg Engineering, Heidelberg, Germany) system. Sodium fluorescein dye (2mL of 25% solution) will be injected intravenously, and video images of the iris vasculature will be recorded as the fluorescent dye circulates through the iris blood vessels. The images will be digitally recorded and assigned the volunteer's study identification number. Data collected from this procedure includes circumferential extent of vascular filling (number of clock hours), radial extent of vascular filling (percent of iris radius), delay in iris circulation (time from dye injection to maximal filling of iris vasculature), blood vessel tortuosity and alterations in caliber. This procedure takes approximately 20 minutes.
- Anterior Segment Optical Coherence Tomography (AS-OCT) will be performed in the surgical eye. The volunteer will be seated at the Visante OCT (Carl Zeiss Meditec, Dublin, CA) in a room with standardized lighting. They will be instructed to look at a visual target within the instrument, and three high-resolution images of the anterior segment of the eye will be acquired and saved, identified only with the volunteer's study identification number. Data collected from this procedure includes iris leaflet thickness and pupil diameter in a controlled lighting situation. This procedure takes approximately 10 minutes.
Surgery will be performed according to the individual surgeon's preferences, including the use of any iris manipulation techniques that are clinically necessary. Surgical parameters will be recorded on a study visit form with the volunteer's study identification number:
- Pupil diameter will be measured with calipers at the beginning of surgery prior to incision, and at the end, after intraocular lens implantation, but prior to instillation of any miotic agents. These time points are before and after any intra-operative iris expansion techniques could be performed. The surgeon will also record whether he/she uses any iris expansion technique (i.e. iris hooks, Malyugin ring, non-standard pupil dilation medications), which one, and at what point in the procedure the technique was employed.
- Iris billowing will be graded as present or absent.
- Iris prolapse will be graded as present or absent.
- Surgical time from incision to dressing will be recorded.
- Surgical complications or any other surgical findings of interest to the surgeon will be recorded.
- Conditions
- Floppy Iris Syndrome
- Keywords
- Flomax, Floppy iris Syndrome, Tamsulosin
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Flomax | Male patients scheduled for cataract surgery with current or past use of Flomax | |
| Control | Male adult patients scheduled for cataract surgery with no history of Flomax use |
What is being measured
The primary outcome is the main question the study is designed to answer.
Intraoperative Floppy Iris Syndrome
Measured: during cataract surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Dec 2010 (estimated)
- Study startJun 2010
- Primary completionDec 2013
- Study completionDec 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Floppy Iris SyndromeStudies of the same condition, open and under way.
- More trials run by University of MichiganThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 36 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Michigan
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Roni Shtein, University of Michigan
- Investigators
- Roni Shtein, MD, Principal investigator, University of Michigan Kellogg Eye Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01252472
- Sponsor's protocol ID
- HUM00039333
- Status last verified
- Apr 2015
- First submitted
- 2 Dec 2010
- Last updated
- 28 Apr 2015
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Apr 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Diagnostic Imaging for Intraoperative Floppy Iris Syndrome
- ClinicalTrials.gov ID
- NCT01252472
- Acronym / sponsor ID
- HUM00039333
- Conditions
- Floppy Iris Syndrome
- Keywords
- Flomax, Floppy iris Syndrome, Tamsulosin
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 36 participants (actual)
- Lead sponsor
- University of MichiganUniversity, hospital or other
- Study start
- Jun 2010
- Primary completion
- Dec 2013 (actual)
- Study completion
- Dec 2013 (actual)
- First posted
- 3 Dec 2010 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Some men who have a history of use of Tamsulosin (Flomax) are at risk for a condition called Intraoperative Floppy Iris Syndrome that can develop during otherwise routine cataract surgery. It is not fully understood why this condition develops or who is at risk for developing it. In this study the investigators will take pictures of the iris and iris blood vessels before cataract surgery. The investigators hope that the results of this study will provide a better understanding of how Intraoperative Floppy Iris Syndrome develops and give us a non-surgical way of figuring out who might develop this problem during surgery.
Detailed description
Male patients scheduled for cataract surgery who are currently taking tamsulosin will be recruited into the study. Age-matched male control patients undergoing cataract surgery, without a history of using any a-adrenergic antagonist medication, will also be recruited. Careful diagnostic iris evaluation using iris Fluorescein Angiography (FA) and Anterior Segment Optical Coherence Tomography (AS-OCT) will be performed prior to cataract surgery. Intraoperative findings and surgical complications will be recorded in an effort to correlate preoperative diagnostic iris FA and AS-OCT findings with presence and severity of intraoperative floppy iris syndrome (IFIS). The investigators hypothesize that males on tamsulosin will have abnormal iris blood vessels on iris FA and altered iris morphology, consistent with iris atrophy, on AS-OCT that will correlate with presence of IFIS and help elucidate the pathophysiology of tamsulosin-induced IFIS.
Male patients scheduled for cataract surgery who are currently taking tamsulosin will be eligible for enrollment into the study if they have no other conditions that affect the iris vasculature and architecture (i.e. diabetes mellitus, glaucoma, pseudoexfoliation syndrome, history of prior eye surgery or eye trauma, use of eye drops other than artificial tears and normal preoperative drops). Control patients will be eligible if they have no history of use of any a-adrenergic antagonist (tamsulosin, alfuzosin, doxazosin, or terazosin). Patients who are interested in participating will be given a copy of the study consent form to take home with them. These patients will then be contacted by the study coordinator for further discussion of the study details. Study volunteers will be asked to come to the Kellogg Eye Center any time prior to their scheduled surgery. Volunteers will undergo the informed consent process, sign the consent form and be given a study identification number, linked to the patient in a de-identified fashion, that will be used exclusively for the study. The link of the study identification number and patient will be kept in a locked cabinet in the clinic coordinator's locked office. All patient study information will be collected and encoded according to HIPAA guidelines and institutional review board approval. The investigators plan to enroll 20 patients and 10 age-matched controls in a 12-month enrollment period.
- Iris Fluorescein Angiography (FA) will be performed in the surgical eye. The volunteer will be seated at the Heidelberg Spectralis (Heidelberg Engineering, Heidelberg, Germany) system. Sodium fluorescein dye (2mL of 25% solution) will be injected intravenously, and video images of the iris vasculature will be recorded as the fluorescent dye circulates through the iris blood vessels. The images will be digitally recorded and assigned the volunteer's study identification number. Data collected from this procedure includes circumferential extent of vascular filling (number of clock hours), radial extent of vascular filling (percent of iris radius), delay in iris circulation (time from dye injection to maximal filling of iris vasculature), blood vessel tortuosity and alterations in caliber. This procedure takes approximately 20 minutes.
- Anterior Segment Optical Coherence Tomography (AS-OCT) will be performed in the surgical eye. The volunteer will be seated at the Visante OCT (Carl Zeiss Meditec, Dublin, CA) in a room with standardized lighting. They will be instructed to look at a visual target within the instrument, and three high-resolution images of the anterior segment of the eye will be acquired and saved, identified only with the volunteer's study identification number. Data collected from this procedure includes iris leaflet thickness and pupil diameter in a controlled lighting situation. This procedure takes approximately 10 minutes.
Surgery will be performed according to the individual surgeon's preferences, including the use of any iris manipulation techniques that are clinically necessary. Surgical parameters will be recorded on a study visit form with the volunteer's study identification number:
- Pupil diameter will be measured with calipers at the beginning of surgery prior to incision, and at the end, after intraocular lens implantation, but prior to instillation of any miotic agents. These time points are before and after any intra-operative iris expansion techniques could be performed. The surgeon will also record whether he/she uses any iris expansion technique (i.e. iris hooks, Malyugin ring, non-standard pupil dilation medications), which one, and at what point in the procedure the technique was employed.
- Iris billowing will be graded as present or absent.
- Iris prolapse will be graded as present or absent.
- Surgical time from incision to dressing will be recorded.
- Surgical complications or any other surgical findings of interest to the surgeon will be recorded.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Flomax | – | –Male patients scheduled for cataract surgery with current or past use of Flomax |
| Control | – | –Male adult patients scheduled for cataract surgery with no history of Flomax use |
Who may qualify
- Ages
- 18 years and older
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Adult male patients seen and scheduled for cataract surgery at the Kellogg eye Centers in Ann Arbor, Livonia and Brighton campuses.
Key inclusion criteria (6 listed)
- Male
- 18 years or older
- Scheduled for Cataract Surgery
- Current or Past use of Tamsulosin (flomax)
- Blue colored iris
Key exclusion criteria (6 listed)
- Females
- Diabetes
- Glaucoma
- Use of medicated eye drops
- Trauma or prior surgery to the eye
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Intraoperative Floppy Iris Syndrome
Time frame: during cataract surgery
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Apr 2015.
Related trials for Floppy Iris Syndrome
Not yet recruitingPhase 4
Iris Structural Changes With Tamsulosin vs. Silodosin in Benign Prostatic Hyperplasia Patients
Benign Prostatic Hyperplasia, Tamsulosin
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Roni Shtein, MD principal investigator
University of Michigan Kellogg Eye Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Floppy Iris Syndrome, run by University of Michigan at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Apr 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Intraoperative Floppy Iris Syndrome (time frame: during cataract surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Apr 2015.